Fluence Selected as LED Technology Partner by Major Cannabis Cultivators in Growing Portuguese Market
2.2.2023 16:30:00 EET | Business Wire | Press release
Fluence, a leading global provider of energy-efficient LED lighting solutions for commercial cannabis and food production, is supporting widespread expansion of pharmaceutical-grade medical cannabis cultivation operations in Portugal.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230202005215/en/
Fluence LEDs in action at the Key Leaves facility in Portugal (Photo: Business Wire)
Portugal’s cannabis laws are among the most progressive in the world, and its established licensing system is ahead of most other European countries. Portugal decriminalized personal cannabis use in 2001 and legalized medical use in 2018. Since then, 20 official licenses for medical cannabis production, processing, import, export or a combination of categories have been issued, and Fluence has been chosen to provide lighting for over half of them.
Key Leaves, a medical cannabis market leader in Portugal, is one of the 20 companies to have received a medical cannabis license from the Portuguese government. The company is focused on delivering premium quality medicinal cannabis products that adhere to the Good Agricultural and Collection Practice (GACP) and Good Distribution Practices (GDP) wholesale standards, along with all relevant Portuguese regulations.
As a fully indoor facility dedicated to research and development, Key Leaves depends on sole-source lighting for its success—completing more than 20 full cultivation cycles using Fluence LED technology. Fluence’s LEDs have helped Key Leaves optimize production and cultivation light cycles, increase plant yield, uniformity and decrease energy consumption.
“To achieve our business objectives using the most effective and efficient production processes possible, we’ve invested in the world-class technologies and partnerships available,” said Alessandro Radici, CEO at Key Leaves. “Fluence’s market-leading LED technology and the on-call support of its research and horticulture teams allow us to cultivate with maximum efficacy, deliver a highly standardized product and guarantee constant supply for our clients.”
Fluence provides LED lighting solutions to 10 other licensed Portuguese medical cannabis producers—including Bathera, Curaleaf International and Clever Leaves, and pre-licensed AceCann—as well as several additional companies that are currently seeking licensing. Bathera, a German company, recently began producing its own medical cannabis and decided to construct its indoor cultivation and manufacturing facility near Lisbon. The site, currently in progress, houses 6,000 square meters of rooms dedicated to cultivation and 3,000 square meters of space for supporting areas, such as a GMP zone, six drying rooms and space for hand trimming and manual packaging.
“Because of the great Portuguese weather, outdoor cultivation is, of course, possible. We performed rigorous research and analysis with every construction decision and, after looking at the various options, we decided that cultivating indoors is the only way to ensure stable, high-quality products,” said Boris Agababov, founder and CEO of Bathera.
Curaleaf International focuses on advancing the therapeutic value of cannabis used for medicinal purposes to develop products that meet the needs of patients across Europe. The company’s commitment to accessibility, research and data-led product excellence brought it to Fluence when a lighting partner was needed for its Portuguese operations.
“Fluence’s goal is to help our customers grow smarter and build efficient economies of scale,” said Jörg Meyer-Brenken, lead account manager of cannabis in EMEA at Fluence. “We are led by science, and the collaborative approach we take to provide our partners with tailored lighting solutions, knowledge and experience has proven irreplaceable, especially for those in emerging medicinal cannabis markets.”
Portuguese native André Lagareiro, Fluence’s dedicated account manager for Portugal, works closely with Fluence’s Portuguese customers to help them identify the right lighting solutions to optimize plant growth and facility operations.
“Helping companies to innovate and advance medical cannabis operations within Portugal’s legislative environment requires a deep understanding of both cannabis cultivation and European regulatory standards,” said Lagareiro. “The unmatched top-of-the-line product, market expertise and quality of service provided by Fluence’s in-house research and development team is the deciding factor for the many Portuguese cannabis companies that have chosen Fluence as their lighting technology partner.”
For more information on Fluence, visit www.fluence.science.
About Fluence
Fluence Bioengineering, Inc. (Fluence) creates powerful and energy-efficient LED lighting solutions for commercial crop production and research applications. Fluence is a leading LED lighting supplier in the global cannabis market and is committed to enabling more efficient crop production with the world’s top vertical farms and greenhouse produce growers. Fluence global headquarters are in Austin, Texas, with its EMEA headquarters in Rotterdam, Netherlands. Fluence operates as a business unit within Signify’s Digital Solutions division. For more information about Fluence, visit www.fluence.science.
About AceCann
AceCann is a Portuguese medical cannabis company that has a cost-efficient, scalable and superior quality organic indoor cultivation and extraction facility near Lisbon. AceCann is focused on the development of new medical delivery forms for cannabis, joining efforts with local and international universities and operating on a flexible structure capable of making fast decisions to scale according to market demands and needs.
About Key Leaves
Key Leaves is a Portuguese-founded company established in 2015 and licensed by Infarmed for the cultivation, import and export of cannabis products. With a multicultural and diversified international team, Key Leaves is proud to be working with some of the most renowned professionals and experts in the medicinal cannabis field.
About Bathera
Bathera is a vertically integrated medical cannabis company with operations in Germany and Portugal. In addition to its state of the art indoor medical cannabis growing facility in Portugal, Bathera, operates two independent wholesalers and importers for medical cannabis in Germany.
About Curaleaf
Curaleaf International (formerly EMMAC Life Sciences Group) is Europe’s largest vertically integrated cannabis company, bringing together pioneering science and research with cutting-edge cultivation, extraction and production. With a unique supply and distribution network throughout Europe, Curaleaf International’s vision is to bring the life-enhancing potential of cannabis to the people who need it. EMMAC Life Sciences was acquired by Curaleaf Holdings in March 2021. For more information about Curaleaf International, please visit www.curaleafinternational.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230202005215/en/
Contact information
For EMEA,
Silvia Nagyova
silvia.nagyova@fluence-led.com
+49 160 93335045
For North America,
Callie Neatherlin
callie@redfancommunications.com
512-439-9720
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Opzelura ® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 14:30:00 EEST | Press release
Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids (TCSs) and topical calcineurin inhibitors (TCIs) are inadequate or inappropriate. “AD is a chronic skin condition that can have a significant impact on daily life. The positive CHMP opinion for Opzelura marks meaningful progress toward bringing the first non-steroidal topical JAK treatment option to adults in Europe with moderate AD for whom standard topical therapies have failed,” said Lee Heeson, Executive Vice President and Head of Incyte International. “If approved by the European Commission, Opzelura could help address an important gap for patients who have limited treatment options when TCSs and TCIs are inadequate or inappropriate.” The positive CHMP o
Datroway ® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 14:00:00 EEST | Press release
Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the TROPION-Breast02phase 3 trial, which werepresented at the 2025 European Society for Medical Oncology Congress and published in Annals of Oncology. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In TROPION-Breast02, Datroway demonstrated a
DAYBU ® (trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 13:49:00 EEST | Press release
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating condition," said Catherine Owen Adams, Acadia’s Chief Executive Officer. “Our commitment is to make a meaningful difference in the lives of patients, caregivers, and the wider Rett com
HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 12:18:00 EEST | Press release
HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi
Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 11:28:00 EEST | Press release
Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom